Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20901309 | 0.84 | KMT2A (0.47) | APLNRKDM1AMAOAMAOBKMT2A | |
| SCHEMBL10888153 | 0.83 | IDO1 (0.46) | APLNRGAAHTR2ACA12CA1 | |
| SCHEMBL11295684 | 0.83 | GPR84 (0.47) | APLNRKDM1AMAOAMAOBKMT2A | |
| SCHEMBL2060421 | 0.83 | HTR2A (0.47) | APLNRHTR2ACA12CA1CA2 | |
| SCHEMBL30486651 | 0.81 | APLNR (0.46) | APLNRMAOAHTR2ACA12CA1 | |
| SCHEMBL1690285 | 0.81 | HTT (0.46) | APLNRKDM1AMAOAMAOBKMT2A | |
| SCHEMBL3527192 | 0.81 | APLNR (0.46) | APLNRMAOAHTR2ACA12CA1 | |
| SCHEMBL13186415 | 0.80 | GAA (0.50) | APLNRKDM1AMAOAMAOBKMT2A | |
| SCHEMBL3723675 | 0.80 | ALDH1A1 (0.42) | KMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3718619 | 0.80 | NQO1 (0.48) | KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230272381-A1 | SINGLE-STRANDED POLYNUCLEOTIDE | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| CN-114450006-A | TrkB positive allosteric modulators | 斯特拉斯堡大学 | 2022-05-06 | — | — | CN | disclosed |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3787669-A1 | COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | The Trustees of Indiana University (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20160214956-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3041836-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-07-13 | — | — | EP | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015033307-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015033307-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-8674101-B2 | Nucleophilic fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-18 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214956-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | APLNR 524/4885KDM1A 2483/4885MAOA 959/4885 |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | APLNR 319/4885KDM1A 2635/4885MAOA 267/4885 |
| US-20230272381-A1 | SINGLE-STRANDED POLYNUCLEOTIDE | TRDMT1, ADAR, TARBP1 | APLNR 310/4885KDM1A 4060/4885MAOA 3972/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | APLNR 853/4885KDM1A 3711/4885MAOA 1487/4885 |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | APLNR 319/4885KDM1A 2635/4885MAOA 267/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | APLNR 319/4885KDM1A 2635/4885MAOA 267/4885 |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | APLNR 938/4885KDM1A 1899/4885MAOA 829/4885 |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | APLNR 256/4885KDM1A 776/4885MAOA 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.